07/01/16-06/30/21
NIH-NIAID K01AI125726 (PI: Davidson)
Genetic Epidemiology of Nontuberculous Mycobacteria for Predicting Host Specificity and Lung Disease Outcomes
Goal: Identify genetic variations in nontuberculous mycobacteria infecting cystic fibrosis (CF) and non-CF patients that are predictive of host specificity, lung disease progression and response to antibiotic treatment.
07/01/17-06/30/19
Vertex Research Innovation Award in Cystic Fibrosis (PI: Davidson)
Genomic Evolution of Nontuberculous Mycobacteria During Cystic Fibrosis Airway Infection
Goal: Identify genomic features and evolutionary trajectories in longitudinally sampled CF-NTM isolates that are associated with clinical outcomes including development of active lung disease and treatment response.
07/01/17-04/30/19
Bill and Melinda Gates Foundation (PI: Walter)
A pathogen-targeted RNAseq method for monitoring treatment responses in human tuberculosis
Goal: Develop a new, culture-independent method of measuring the effectiveness of tuberculosis treatment in humans.
Role: Co-Investigator
11/01/17-10/31/19
Cystic Fibrosis Foundation (PI: Nick)
Molecular Basis for Combination Drug Failure in the Treatment of NTM
Goal: Identify and validate a transcriptomic signature for azithromycin-induced antagonism of amikacin in well-phenotyped Mycobacterium abscessus isolates from CF patients.
Role: Co-Investigator
03/01/18-02/28/20
Cystic Fibrosis Foundation (PI: Nick)
Cross-platform Comparison of Novel Markers of NTM in the CF Airway
Goal: Test the sensitivity and specificity of a suite of culture-independent markers of NTM, compared to standard sputum culture, and correlate with patient NTM phenotype.
Role: Co-Investigator
